Please enter your login and password
Don't have an account? Sign Up! 161 lens
Please enter your email address
To create a free account, please fill out the form below.
Already have an account? Login
Vision Marine Technologies Announces Closing of Private Placement
i-80 Gold Announces Pricing of Prospectus Offering
Cognizant Study Shows Consumers Who Embrace AI Could Drive $4.4 T...
Gordon Ramsay Burger Celebrates its Grand Opening at Flamingo Las...
RBB Bancorp Declares Quarterly Cash Dividend of $0.16 Per Common ...
ECOPETROL S.A. reports on the decision adopted by the Court of th...
Vision Marine Technologies Announces Closing of Private Placement
i-80 Gold Announces Pricing of Prospectus Offering
Cognizant Study Shows Consumers Who Embrace AI Could Drive $4.4 T...
Gordon Ramsay Burger Celebrates its Grand Opening at Flamingo Las...
RBB Bancorp Declares Quarterly Cash Dividend of $0.16 Per Common ...
ECOPETROL S.A. reports on the decision adopted by the Court of th...
RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company's installed base reached 971 LDDs, a 46% increase from Q4 2023.
Full-year 2024 revenue is expected at $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region's premium IOL market.
For 2025, RxSight projects revenue between $185.0-197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses of $165.0-170.0 million. Cash position as of December 31, 2024, was $237.2 million.
RxSight (NASDAQ: RXST) reported preliminary fourth-quarter 2024 revenue of $40.2 million, up 41% from the prior year, driven by sales of 29,069 Light-Adjustable Lenses (LAL™/LAL+ ®) and 83 Light Delivery Devices (LDD™s). The number of LDDs installed by the company reached 971, an increase of 46% compared to the fourth quarter of 2023.
Total revenue for 2024 is forecast at $139.9 million, a growth of 57%, having sold 98,055 LALs and installed 305 LDDs. Currently, the company serves approximately 15% of cataract surgeons in North America, with LAL procedures accounting for more than 10% of the premium IOL market in the region.
For 2025, RxSight expects revenue between $185.0 and $197.0 million (32-41 percent growth), with a gross profit margin of 71-73 percent and operating expenses between $165.0 and $170. 0 million dollars. The liquidity position as of December 31, 2024 was $237.2 million.
RxSight (NASDAQ: RXST) reported preliminary fourth-quarter 2024 revenue of $40.2 million, an increase of 41% year over year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices. Light (LDD™s). The company's installed base reached 971 LDDs, an increase of 46% compared to the fourth quarter of 2023.
Full year 2024 revenue is expected to be $139.9 million, representing 57% growth, with 98,055 LAL sold and 305 LDD installed. The company now serves approximately 15% of cataract surgeons in North America, with LAL procedures representing more than 10% of the premium IOL market in the region.
For 2025, RxSight projects revenue between $185.0 and $197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses between $165.0 and $170.0 million. The cash position as of December 31, 2024 was $237.2 million.
RxSight (NASDAQ: RXST) reported projected fourth-quarter 2024 revenue of $40.2 million, up 41% year-over-year. This was driven by sales of 29,069 adjustable optical lenses (LAL™/LAL+®) and 83 light delivery devices (LDD™s). The company's installed number of LDDs reached 971, a 46% increase compared to the fourth quarter of 2023.
Full-year 2024 revenues are expected to be $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company currently supports 15% of cataract surgeons in North America, and LAL procedures account for more than 10% of the premium IOL market in the region.
For 2025, RxSight projects revenue to be between $185 million and $197 million (32-41% growth), gross margin of 71-73%, and operating expenses of $165 million to $100 million. It is expected to be worth $70 million. As of December 31, 2024, its cash reserves were $237.2 million.
RxSight (NASDAQ: RXST) reported preliminary fourth quarter 2024 revenue of $40.2 million, up 41% year-over-year, driven by the sale of 29,069 Adjustable Lenses to Light (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company's installed base reached 971 LDD, an increase of 46% compared to the fourth quarter of 2023.
Annual revenue for 2024 is expected to be $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of cataract surgeons in North America, with ALL procedures accounting for more than 10% of the premium IOL market in the region.
For 2025, RxSight forecasts revenues of $185.0 to $197.0 million (32 to 41 percent growth), with gross profit margins of 71 to 73 percent and operating expenses of 165.0 to 170.0 million dollars. The cash position as of December 31, 2024 was $237.2 million.
RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year over year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 light delivery devices (LDD™s). The company's installed inventory reached 971 LDDs, an increase of 46% compared to the fourth quarter of 2023.
Full-year 2024 revenue is expected to be $139.9 million, up 57%, with 98,055 LAL sold and 305 LDD installed. The company now serves approximately 15% of cataract surgeons in North America, with LAL procedures accounting for over 10% of the premium IOL market in the region.
For 2025, RxSight expects revenues between $185.0 million and $197.0 million (32-41% growth), with gross margins of 71-73% and operating expenses of $165.0-170.0 million. The liquidity position as of December 31, 2024 was $237.2 million.
The preliminary Q4 results showcase exceptional performance with revenue reaching $40.2M, marking a 41% YoY growth. The full-year revenue of $139.9M significantly outperformed initial guidance, driven by robust LAL sales growth of 79%. The healthy cash position of $237.2M provides substantial runway for expansion plans.
The market penetration metrics are particularly impressive - capturing 15% of North American cataract surgeons and 10% of the premium IOL market. The projected 2025 revenue guidance of $185-197M implies continued strong growth of 32-41%, while the anticipated gross margin of 71-73% indicates operational efficiency and pricing power.
The projected operating expenses of $165-170M for 2025 suggest significant investment in growth initiatives, including international expansion and product innovation. While this may impact near-term profitability, it positions the company for sustained long-term growth in the premium ophthalmology market.
The accelerating adoption of the RxSight system reflects a paradigm shift in cataract surgery outcomes. The installation of 971 LDDs represents critical mass achievement, creating a network effect that could drive faster market penetration. The 61% increase in LAL procedures indicates strong surgeon confidence and patient satisfaction.
The planned expansion into Asian and European markets presents significant growth potential, given the aging demographics and higher cataract surgery volumes in these regions. The company's focus on innovation and system improvements suggests a strategic approach to maintaining technological leadership in the premium IOL segment.
In simple terms: Think of this like a high-tech adjustable lens that's quickly becoming the preferred choice for eye surgeons. The company has installed nearly 1,000 special machines that allow doctors to fine-tune these lenses after surgery, leading to better vision outcomes for patients. They're now planning to take this technology global while continuing to make it even better.
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
Preliminary Unaudited Fourth Quarter and Full-year 2024 Results
“During the fourth quarter, we achieved record highs for LDD sales and LAL procedures, meaningfully exceeding our initial full-year 2024 revenue guidance. With nearly one thousand LDDs installed, we now serve an estimated 15% of cataract surgeons in North America, while LAL procedures account for over 10% of the region’s premium IOL market. We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “In 2025, we expect adoption for the RxSight system to remain strong as we collaborate with a diverse range of customers to further expand the infrastructure for post-operative light treatments. Building on our momentum in North America, we also look forward to entering key international markets in Asia and Europe. Finally, leveraging the foundation established since our initial FDA approval, we plan to continue to innovate the RxSight system, that we believe will continue to set the standard for the premium IOL market for years to come.”
RxSight anticipates full-year 2025 revenue in the range of $185.0 million to $197.0 million, reflecting growth of approximately 32% to 41% over 2024. The company currently estimates the full-year 2025 gross profit margin to be in the 71% to 73% range. In addition, the company expects full-year 2025 operating expenses in the range of $165.0 million to $170.0 million, including non-cash stock-based compensation expense guidance in the range of $22.0 million to $25.0 million.
The Company’s fourth quarter and full-year 2024 financial and operational results are preliminary and are subject to the completion of the Company’s 2024 audit. Audited full-year 2024 and unaudited fourth quarter 2024 financial results are expected to be announced in February 2025.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
This press release contains forward-looking statements, including: statements concerning: the growing recognition of superior outcomes enabled by adjustability; the Company’s preliminary unaudited fourth quarter and fiscal 2024 financial and operational results and the anticipated timing of announcing audited full-year 2024 and unaudited fourth quarter 2024 financial results; the expectation of strong adoption for the RxSight system; the Company’s plans to enter international markets; the Company’s plans to continue innovating the RxSight system, that it believes will set the standard for the premium IOL market for the years to come; the potential of the Company’s technology and management’s plans related thereto; and the Company’s projected revenue, gross profit margin, operating expenses and non-cash expenses in 2025. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, and any subsequent filings with the SEC. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. The foregoing financial and operational results are preliminary estimates. We are in the process of finalizing our financial statements for the year ended December 31, 2024, and our actual results remain subject to completion of those financial statements and their audit by our independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. Our actual, reported results of operations could differ based on completion of our year end closing procedures, final adjustments and developments that may arise prior to completion of our annual financial statements, and adjustments arising from the audit by our independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2024 when they become available. Company contact: Shelley B. Thunen Chief Financial Officer sthunen@rxsight.com
Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com
What was RxSight's (RXST) revenue growth in Q4 2024? RxSight's Q4 2024 revenue grew 41% year-over-year to $40.2 million.
How many Light Adjustable Lenses (LAL) did RXST sell in 2024? RxSight sold 98,055 Light Adjustable Lenses in 2024, representing a 79% increase from 2023.
What is RXST's revenue guidance for 2025? RxSight projects 2025 revenue between $185.0-197.0 million, representing 32-41% growth over 2024.
What was RxSight's (RXST) market penetration in North America by end of 2024? RxSight served approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region's premium IOL market.
cr 39 lenses What is RXST's projected gross profit margin for 2025? RxSight expects a gross profit margin between 71-73% for 2025.